ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers

SRC: A Century of Science Brought to the Clinic

(2015) Alexey Aleshin et al.   NEOPLASIA

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

(2011) Devika Gajria et al.   Expert Review of Anticancer Therapy

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Sequence-Dependent Oligomerization of the Neu Transmembrane Domain Suggests Inhibition of “Conformational Switching” by an Oncogenic Mutant

(2010) Andrew J. Beevers et al.   BIOCHEMISTRY

The impact of CFNS-causing EFNB1 mutations on ephrin-B1 function

(2010) Roman Makarov et al.   BMC Medical Genetics

PTPL1/PTPN13 Regulates Breast Cancer Cell Aggressiveness through Direct Inactivation of Src Kinase

(2010) Murielle Glondu-Lassis et al.   CANCER RESEARCH

Src Inhibitors in Lung Cancer: Current Status and Future Directions

(2010) Sacha I. Rothschild et al.   Clinical Lung Cancer

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

(2010) Silvia Schenone et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173

(2010) Lu Kong et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus–Related Head and Neck Cancer

(2009) William C. Spanos et al.   ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

(2009) Shawn P. Fessler et al.   BREAST CANCER RESEARCH AND TREATMENT

SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer

(2009) Fred Saad et al.   CANCER TREATMENT REVIEWS

Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck

(2009) J. Niu et al.   CARCINOGENESIS

HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma

(2009) Łukasz Kruszyna et al.   CLINICAL BIOCHEMISTRY

c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential

(2009) R. Marcotte et al.   MOLECULAR AND CELLULAR BIOLOGY

Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway

(2009) A C Hoover et al.   ONCOGENE

PTPL1: a large phosphatase with a split personality

(2008) Ogan D. Abaan et al.   CANCER AND METASTASIS REVIEWS

Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer

(2008) Mohammad Jahanzeb   Clinical Breast Cancer

Fibroblast Growth Factor Receptor-induced Phosphorylation of EphrinB1 Modulates Its Interaction with Dishevelled

(2008) Hyun-Shik Lee et al.   MOLECULAR BIOLOGY OF THE CELL

The Val allele of HER-2 codon 655 predicts the progression of oral squamous cell carcinoma

(2008) Cheng-Hsien Wu et al.   ORAL ONCOLOGY